The United Laboratories International Holdings ( (HK:3933) ) has provided an update.
The United Laboratories International Holdings Limited announced that their UBT251 Injection, a class 1 innovative new drug developed for chronic kidney disease, has received approval for phase II clinical trials by the China National Medical Products Administration. UBT251, a long-acting triple agonist, has demonstrated superior therapeutic effects compared to existing treatments in preclinical studies and positions the company as a key player in the biopharmaceutical industry’s research and development sector. This approval marks a significant step in enhancing the company’s competitiveness and potential benefits for shareholders.
More about The United Laboratories International Holdings
The United Laboratories International Holdings Limited is a company incorporated in the Cayman Islands with limited liability, focusing on pharmaceutical and biotechnology products. It engages in the development and production of innovative drugs, with a particular emphasis on biopharmaceuticals.
YTD Price Performance: -5.06%
Average Trading Volume: 1,200
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $2.71B
Find detailed analytics on 3933 stock on TipRanks’ Stock Analysis page.